Current oncology最新文献

{"title":"Comparative Analysis of Long-Term Renal Outcomes in Upper Tract Urothelial Carcinoma: Local Ablation Versus Radical Nephroureterectomy.","authors":"Blake R Baer, Meghan V Matheny, Raidizon H Mercedes, Jay D Raman","doi":"10.3390/curroncol32030125","DOIUrl":"10.3390/curroncol32030125","url":null,"abstract":"<p><p><b>(1) Background</b>: Upper tract urothelial carcinoma (UTUC) is typically managed through radical nephroureterectomy (RNU) or local ablation (LA). Compared to RNU, LA offers nephron-sparing benefit for select patients but may present increased recurrence risk. This study primarily compares long-term differences between LA and RNU in chronic kidney disease (CKD) progression, estimated glomerular filtration rate (eGFR) decline, all-cause mortality, and need for dialysis. <b>(2) Methods</b>: A retrospective cohort study was conducted using the TriNetX database, examining patients with UTUC treated with RNU (<i>n</i> = 2007) or LA (<i>n</i> = 4172). Propensity score matching balanced both cohorts (<i>n</i> = 1965 per group). Risk ratios and hazard ratios with 95% confidence intervals were calculated over 10 years. <b>(3) Results</b>: At 10 years, LA preserved higher mean eGFR (53.49 vs. 46.72; <i>p</i> < 0.001) and lower mean creatinine (1.56 vs. 1.66; <i>p</i> = 0.017). However, LA held a higher incidence of end-stage renal disease (ESRD) (3.6% vs. 2.2%, <i>p</i> = 0.008) and all-cause mortality (26.7% vs. 23.5%, <i>p</i> = 0.016). There was no significant difference in rates of dialysis (<i>p</i> = 0.79). <b>(4) Conclusions</b>: RNU did not carry an increased risk of ESRD, advanced stages of CKD, need for renal dialysis, or overall mortality compared with LA. LA may delay but not totally prevent renal dysfunction when compared to RNU, and exhibits a more gradual timeline.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma.","authors":"Ellery Koelker-Wolfe, Karen J Marcus, Steven G DuBois, Paul J Catalano, Suzanne Shusterman, Myrsini Ioakeim-Ioannidou, Hesham Elhalawani, Torunn I Yock, Shannon M MacDonald, Daphne A Haas-Kogan, Kevin X Liu","doi":"10.3390/curroncol32030124","DOIUrl":"10.3390/curroncol32030124","url":null,"abstract":"<p><p><b>Introduction:</b> While palliative radiotherapy (RT) is frequently used in the management of relapsed/refractory high-risk neuroblastoma (HR-NBL); outcomes after palliative hypofractionated RT (hypo-RT) remain poorly characterized. <b>Methods</b>: We conducted a multi-institutional retrospective study of 38 patients who were diagnosed with HR-NBL between 1997 and 2021 and received palliative RT. Conventional RT (conv-RT) and hypo-RT were defined as palliative treatment courses using dose ≤2 or >2 Gy per fraction, respectively. The primary outcome was cumulative incidence of in-field progression using Gray's test. Univariate analyses were performed using the Cox proportional hazards model. <b>Results</b>: When analyzing by first course of palliative RT, 16 patients received conventionally fractionated RT (43%) and 21 received hypo-RT (57%). Clinical characteristics were similar between the two groups. With a median follow-up of 10.3 months (range: 0.3-104.0), the cumulative incidence of in-field progression was not statistically significantly different between hypo-RT and conv-RT (30% vs. 20% at 10 months; <i>p</i> = 0.80). Clinical response, defined as symptomatic improvement or decrease in the size of the lesion, was not statistically different between the two groups (92% conv-RT vs. 90% hypo-RT; <i>p</i> = 1.00). No grade ≥4 toxicities were observed. On univariate analysis, hypo-RT (HR 1.50; 95% CI 0.47-4.76; <i>p</i> = 0.493) was not statistically significantly associated with time to in-field progression, but <i>MYCN</i> amplification was associated with significantly longer time to in-field progression (HR: 0.20; 95% CI: 0.05-0.77; <i>p</i> = 0.020). <b>Conclusions</b>: We found no statistically significant difference in cumulative incidence of in-field progression and clinical outcomes between the conv-RT and hypo-RT groups. Palliative hypo-RT can be considered for relapsed/refractory HR-NBL, especially when shorter treatments may offer improved quality of life.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV and Cervical Cancer-Biology, Prevention, and Treatment Updates.","authors":"Emilia Włoszek, Kamila Krupa, Eliza Skrok, Michał Piotr Budzik, Andrzej Deptała, Anna Badowska-Kozakiewicz","doi":"10.3390/curroncol32030122","DOIUrl":"10.3390/curroncol32030122","url":null,"abstract":"<p><p>One of the most significant breakthroughs in cancer research has been the identification of persistent infection with certain human papillomaviruses (HPV) genotypes as the cause of cervical cancer. Since then, a range of diagnostic and therapeutic methods has been developed based on this discovery. This article aims to describe the latest updates in the biology, prevention, and treatment of HPV-related cervical cancer. The current state of knowledge regarding vaccinations, diagnostic tests, and cervical cancer therapies is presented. The latest WHO guidelines on vaccinations are presented, as well as announcements of upcoming changes. The final part of the article summarizes promising new diagnostic and treatment methods, as well as perspectives and the latest research findings on self-administered diagnostic tests, the use of therapeutic vaccines, and circulating cell-free DNA in diagnosis. Despite the significant progress made in recent years, the strategy based on vaccination and testing remains the cornerstone in the fight against HPV-related cervical cancer.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basal Cell Carcinoma in Patients over 80 Years Presenting for Surgical Excision: Clinical Characteristics and Surgical Outcomes.","authors":"Konstantinos Seretis, Nikos Bounas, Erasmia Rapti, Evangeli Lampri, Vasilios Moschovos, Efstathios G Lykoudis","doi":"10.3390/curroncol32030120","DOIUrl":"10.3390/curroncol32030120","url":null,"abstract":"<p><p><b>Background.</b> Complete basal cell carcinoma (BCC) excision remains the most common treatment modality. However, its clinical characteristics and the surgical outcomes achieved in patients over 80 years-often with several medical comorbidities and potentially limited life expectancy-have not been thoroughly examined. This clinical study aims to investigate tumor-specific characteristics and surgical outcomes following surgical treatment of BCC in older individuals. <b>Methods.</b> An observational cohort study based on a prospectively maintained database was conducted in a tertiary center using a predetermined protocol. Patients who underwent BCC surgery between January 2010 and September 2024 were included and grouped by age under or over 80 years. The inclusion criterion was a histologically confirmed BCC, while patients with syndromes predisposing BCC development were excluded. <b>Results.</b> Among the 1396 biopsy-proven BCCs, 35% of the patients were older than 80 years. No significant differences were observed in their baseline characteristics. The pathogenic capacity was greater in elderly patients, who exhibited higher rates of multiple and concurrent skin cancers, larger BCC diameters, and routine involvement in high-risk areas. More lesions were classified as high-risk for recurrence, and the surgical treatment was accompanied by a higher frequency of positive or close margins, high-grade subtypes, and perineural invasion. Logistic regression of 1150 BCCs revealed that age > 80, advanced TNM stage, and margin status robustly predict high-risk histology and high NCCN risk of tumor recurrence. <b>Conclusions.</b> This study highlights that BCC in the elderly population tends to present with a more aggressive tumor status, based on the key clinical and pathology features. These findings underscore the need for tailored surgical strategies in this population.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD8⁺CD28⁺PD1^- T Cells as a Prognostic Biomarker in Endometrial Cancer.","authors":"Yufei Nie, Lin Yang, Yanan Zhang, Hongyan Guo","doi":"10.3390/curroncol32030121","DOIUrl":"10.3390/curroncol32030121","url":null,"abstract":"<p><p>Endometrial cancer (EC) is an immunogenic tumor, with CD8⁺ T cells playing a pivotal role in antitumor immunity. Overexpression of PD1 suppresses T cell function by inhibiting CD28, a critical co-stimulatory molecule. Classifying CD8⁺ T cells based on PD1 and CD28 expression provides valuable insights into the immune microenvironment of EC. Peripheral blood samples from 120 EC patients and tumor tissue samples from 81 EC patients were analyzed via flow cytometry. CD8⁺ T cells were categorized according to PD1 and CD28 expression, and their associations with clinical characteristics were systematically evaluated. Peripheral CD28^-/CD8⁺ and PD1⁺/CD8⁺ T cell proportions were significantly associated with several high-risk factors, including deep myometrial invasion, and LVSI, as well as metabolic disorders such as dyslipidemia. Peripheral CD28⁺PD1^-/CD8⁺ T cells were associated with stage, grade, and LVSI, inversely correlated with age, and elevated in patients with hypertension or dyslipidemia. Tumor-infiltrating CD28⁺PD1^-/CD8⁺ T cells were associated with tumor grade and LVSI, with multivariate analysis identifying low proportions as an independent predictor of relapse. In summary, CD8⁺CD28^- and CD8⁺PD1⁺ T cells are linked to high-risk clinical features in EC, while tumor-infiltrating CD8⁺CD28⁺PD1^- T cells serve as a key independent prognostic marker for relapse. Additionally, CD8⁺CD28^-, CD8⁺PD1⁺, and CD8⁺CD28⁺PD1^- T cell proportions in PBMC are closely associated with metabolic disorders, emphasizing their potential as biomarkers for immune and metabolic interactions in EC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer.","authors":"Juan A Encarnación Navarro, Virginia Morillo Macías, María Borrás Calbo, Isabel De la Fuente Muñoz, Antonio Lozano Martínez, Vicente García Martínez, Luis Fernández Fornos, Miriam Guijarro Roche, Osamah Amr Rey, Raquel García Gómez","doi":"10.3390/curroncol32030119","DOIUrl":"10.3390/curroncol32030119","url":null,"abstract":"<p><p><b>Background:</b> The management of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved significantly in recent years due to the introduction of androgen receptor-targeted agents (ARTAs). When used alongside androgen deprivation therapy (ADT), these treatments have shown improved oncological results and enhanced survival rates for patients with this condition. <b>Objectives:</b> The objective of this study was to describe the decline in prostate-specific antigen (PSA), the oncological outcomes, and the toxicity profile of mHSPC patients treated with apalutamide. <b>Materials and Methods:</b> Clinical data obtained from seven national hospitals were utilized between March 2021 and July 2024. PSA responses were collected at 3, 6, 12, 18, and 24 months, along with adverse effects reported by patients, dose reductions, or drug discontinuations. The association between PSA decline and progression-free survival (PFS) was evaluated with respect to metastasis volume, location, and timing of diagnosis. <b>Results:</b> A total of 432 patients were included, of whom 40% were de novo cases, and the greater part were classified as M1b. After one year, a reduction of more than 90% in PSA levels was observed in 88.2% of cases, with undetectable levels (≤0.2 ng/mL) achieved in 81.7% of them. The drug was discontinued in 76 patients (15.6%), with adverse effects reported in 7.8% (grade 3) and 1.9% (grade 4). Regarding PSA levels <0.02 ng/mL, promising results were observed, with ultralow PSA (UL2) achieved in 43% of cases at 6 months. <b>Conclusions:</b> This study revealed strong oncological outcomes, with rapid and profound PSA declines and drug safety consistent with emerging evidence. The distinctive finding of this study underscores the importance of a rapid and profound response (UL PSA) as a predictor of better oncological outcomes.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gamma-Glutamyl Transferase Plus Carcinoembryonic Antigen Ratio Index: A Promising Biomarker Associated with Treatment Response to Neoadjuvant Chemotherapy for Patients with Colorectal Cancer Liver Metastases.","authors":"Yanjiang Yin, Bowen Xu, Jianping Chang, Zhiyu Li, Xinyu Bi, Zhicheng Wei, Xu Che, Jianqiang Cai","doi":"10.3390/curroncol32020117","DOIUrl":"10.3390/curroncol32020117","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer liver metastasis (CRLM) is a significant contributor to cancer-related illness and death. Neoadjuvant chemotherapy (NAC) is an essential treatment approach; however, optimal patient selection remains a challenge. This study aimed to develop a machine learning-based predictive model using hematological biomarkers to assess the efficacy of NAC in patients with CRLM.</p><p><strong>Methods: </strong>We retrospectively analyzed the clinical data of 214 CRLM patients treated with the XELOX regimen. Blood characteristics before and after NAC, as well as the ratios of these biomarkers, were integrated into the machine learning models. Logistic regression, decision trees (DTs), random forest (RF), support vector machine (SVM), and AdaBoost were used for predictive modeling. The performance of the models was evaluated using the AUROC, F1-score, and external validation.</p><p><strong>Results: </strong>The DT (AUROC: 0.915, F1-score: 0.621) and RF (AUROC: 0.999, F1-score: 0.857) models demonstrated the best predictive performance in the training cohort. The model incorporating the ratio of post-treatment to pre-treatment gamma-glutamyl transferase (rGGT) and carcinoembryonic antigen (rCEA) formed the GCR index, which achieved an AUROC of 0.853 in the external validation. The GCR index showed strong clinical relevance, predicting better chemotherapy responses in patients with lower rCEA and higher rGGT levels.</p><p><strong>Conclusions: </strong>The GCR index serves as a predictive biomarker for the efficacy of NAC in CRLM, providing a valuable clinical reference for the prognostic assessment of these patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage Ultrasound-Guided Robot-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) as a Metastasis-Directed Therapy (MDT) in Oligoprogressive Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case Report and Review of the Literature.","authors":"Rafał B Drobot, Marcin Lipa, Artur A Antoniewicz","doi":"10.3390/curroncol32020115","DOIUrl":"10.3390/curroncol32020115","url":null,"abstract":"<p><p><b>Background</b>: Metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to progression despite androgen deprivation therapy (ADT). Current treatments, including androgen receptor-targeted agents, chemotherapy, bone-targeted agents, and PARP inhibitors, extend survival but face challenges, such as resistance, adverse effects, and limited durability. Metastasis-directed therapies (MDTs), such as stereotactic ablative radiotherapy (SABR), show promise in oligometastatic disease, but their role in oligoprogressive mCRPC is unclear. Salvage lymphadenectomy is rarely pursued due to invasiveness and limited data. This is the first report of robotic surgery as an MDT in this setting, demonstrating the potential of salvage robot-assisted video-endoscopic inguinal lymphadenectomy (RAVEIL) to manage oligoprogressive mCRPC and delay systemic progression. <b>Methods</b>: A 47-year-old male with metastatic hormone-sensitive prostate cancer (Gleason 10) underwent ADT, docetaxel chemotherapy, and radical retropubic prostatectomy with super-extended pelvic and retroperitoneal lymphadenectomy. Upon progression to oligoprogressive mCRPC, 68Ga-PSMA PET/CT detected a single metastatic inguinal lymph node. Salvage RAVEIL was performed using the da Vinci X™ Surgical System, guided by preoperative ultrasound mapping. <b>Results</b>: Histopathology confirmed metastasis in one of the eight excised lymph nodes. The patient achieved undetectable PSA levels and prolonged biochemical progression-free survival. Minor complications (lymphorrhea, cellulitis) resolved without sequelae. No further progression was observed for over 14 months. <b>Conclusions</b>: This case highlights RAVEIL as a viable MDT option for oligoprogressive mCRPC, potentially extending progression-free intervals while minimizing systemic treatment.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma.","authors":"Shiliang Ge, Kylie Lepic, Ravi Bhindi, Tobias Berg, Dina Khalaf, Brian Leber, Michael Radford, Irwin Walker, Gwynivere Davies, Alejandro Garcia-Horton","doi":"10.3390/curroncol32020118","DOIUrl":"10.3390/curroncol32020118","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate real-world clinical outcomes and transplant-related complications of allogeneic stem cell transplantation (alloSCT) for Hodgkin lymphoma (HL).</p><p><strong>Methods: </strong>This was a single-centre, retrospective analysis of relapsed and refractory (R/R) HL patients who received an alloSCT between 1 January 2016 and 29 February 2024 in Hamilton, Ontario. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), non-relapse mortality (NRM), and graft-versus-host disease/relapse-free survival (GRFS).</p><p><strong>Results: </strong>Twenty-one patients were identified, with thirteen (62%) pre-treated with programmed death 1 (PD-1) blockade with either nivolumab or pembrolizumab. Seventeen (81%) patients underwent related haploidentical donor transplants, while four (19%) patients received a matched unrelated donor transplant. The 2-year OS and PFS rates were 79% (95% CI: 53-92%) and 63% (95% CI: 37-81%), respectively. Trends towards improved OS, PFS, NRM, and GRFS in PD-1-inhibitor-exposed patients were observed. All PD-1-inhibitor-exposed patients who were in complete remission proceeding to alloSCT remained alive at the last follow-up visit. Among the nine patients in partial remission at the time of alloSCT, three deaths were reported, with a 2-year OS of 61%.</p><p><strong>Conclusions: </strong>Our outcome data of a single-centre, heavily pre-treated cohort of Canadian patients confirm that alloSCT with post-transplant cyclophosphamide-based immunosuppression, which has been associated with improvements in PFS, remains a safe and feasible treatment option for patients with R/R HL in the era of checkpoint inhibitor use.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI in Oral Tongue Squamous Cell Carcinoma: A Radiomic Approach in the Local Recurrence Evaluation.","authors":"Antonello Vidiri, Vincenzo Dolcetti, Francesco Mazzola, Sonia Lucchese, Francesca Laganaro, Francesca Piludu, Raul Pellini, Renato Covello, Simona Marzi","doi":"10.3390/curroncol32020116","DOIUrl":"10.3390/curroncol32020116","url":null,"abstract":"<p><p>(1) Background: Oral tongue squamous cell carcinoma (OTSCC) is a prevalent malignancy with high loco-regional recurrence. Advanced imaging biomarkers are critical for stratifying patients at a high risk of recurrence. This study aimed to develop MRI-based radiomic models to predict loco-regional recurrence in OTSCC patients undergoing surgery. (2) Methods: We retrospectively selected 92 patients with OTSCC who underwent MRI, followed by surgery and cervical lymphadenectomy. A total of 31 patients suffered from a loco-regional recurrence. Radiomic features were extracted from preoperative post-contrast high-resolution MRI and integrated with clinical and pathological data to develop predictive models, including radiomic-only and combined radiomic-clinical approaches, trained and validated with stratified data splitting. (3) Results: Textural features, such as those derived from the Gray-Level Size-Zone Matrix, Gray-Level Dependence Matrix, and Gray-Level Run-Length Matrix, showed significant associations with recurrence. The radiomic-only model achieved an accuracy of 0.79 (95% confidence interval: 0.69, 0.87) and 0.74 (95% CI: 0.54, 0.89) in the training and validation set, respectively. Combined radiomic and clinical models, incorporating features like the pathological depth of invasion and lymph node status, provided comparable diagnostic performances. (4) Conclusions: MRI-based radiomic models demonstrated the potential for predicting loco-regional recurrence, highlighting their increasingly important role in advancing precision oncology for OTSCC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}